- Specialty
-
Onco-hepatology (hepatocellular carcinoma, cholangiocarcinoma, rare liver cancers)
- Hospital
-
Hôpital Beaujon (Clichy)
- Latest articles
-
-
Current Perspectives on the Use of Adjuvant Pembrolizumab for Hepatocellular Carcinoma.
(Sep 16, 2026)
-
An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
(Sep 14, 2026)
-
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
(Sep 1, 2026)
-
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).
(Aug 6, 2026)
-
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.
(Aug 1, 2026)
